Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETX2514SUL vs colistin for carbapenem-resistant Acinetobacter infections
CTR20191711Phase 3Completed
- Sponsor
- Zai Lab
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sulbactam + durlobactam in Acinetobacter baumannii-calcoaceticus complex infection, Acinetobacter infection, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), pneumonia, sponsored by Zai Lab. Started Jan 2020; status: completed.
02
Drugs
sulbactam + durlobactam
03
Conditions
Acinetobacter baumannii-calcoaceticus complex infectionAcinetobacter infectionhospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)pneumonia
Beyond the preview
Go deeper on CTR20191711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191711.